Institutional members access full text with Ovid®

Share this article on:

Development and Impact of Human Papillomavirus Vaccines

DARUS, CHRISTOPHER J. MD; MUELLER, JENNIFER J. MD

Clinical Obstetrics & Gynecology: March 2013 - Volume 56 - Issue 1 - p 10–16
doi: 10.1097/GRF.0b013e31827af770
Screening Tests for Cervical Cancer

Cervical cancer is a global health crisis that disproportionately affects developing nations and underserved populations. Two vaccines targeting HPV-16 and 18, which account for 70% of invasive cervical carcinomas, are licensed in the United States and numerous countries worldwide. Both vaccine formulations have shown excellent efficacy with minimal toxicity. Numerous questions remain, including cost-effectiveness, vaccination of males, societal acceptance of HPV vaccination, and cervical dysplasia screening in the HPV-immunized population. Access to vaccination for underserved populations both in developed and resource-poor nations remains an issue. Multivalent vaccines that encompass additional oncogenic HPV strains are under development.

Division of Gynecologic Oncology, Maine Medical Center, Portland, Maine

The authors declare that they have nothing to disclose.

Correspondence: Christopher J. Darus, MD, Division of Gynecologic Oncology, Maine Medical Center, Scarborough, ME. E-mail: cdarus@gmail.com

© 2013 Lippincott Williams & Wilkins, Inc.